Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA, SNOAW), a specialty pharmaceutical company based in Petaluma, reported record quarterly prescriptions filled for the company’s dermatology products.

The number of prescriptions filled during the second quarter, ended in June, was 17,180, up 24 percent over 13,795 in the first quarter and 46 percent over 11,787 in the second quarter of 2016.

Here are gains in first-quarter orders for specific products, reported Thursday: Alevicyn for atopic dermatitis, up 26 percent; Celacyn for scar treatment, up 31 percent; Mondoxyne for severe acne, up 31 percent; and recently launched Sebuderm for seborrheic dermatitis, up 42 percent.

The company stated that growth came after a 2014 decision to focus on launching products in the U.S. using its own salesforce.

“This initiative has been led by dermatology veterans, launching five product lines and growing this business from zero to over 17,000 prescriptions filled in the June 2017 quarter,” the company’s announcement stated.

“Since March 2015, for the last nine quarters, our average quarter-over-quarter growth of prescriptions filled has been 20 percent,” said Robert Miller, chief financial officer.

Headquartered in Petaluma, the company has manufacturing operations in the U.S. and Latin America. European marketing and sales is headquartered in Roermond, Netherlands.